Hepatectomy risk assessment with functional magnetic resonance imaging (HEPARIM)
Abstract Background Post hepatectomy liver failure (PHLF) remains a significant risk in patients undergoing curative liver resection for cancer, however currently available PHLF risk prediction investigations are not sufficiently accurate. The Hepatectomy risk assessment with functional magnetic res...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-10-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-021-08830-4 |
| _version_ | 1819024775850229760 |
|---|---|
| author | Mohamed Elsharif Matthew Roche Daniel Wilson Susmita Basak Ian Rowe Dhakshina Vijayanand Richard Feltbower Darren Treanor Lee Roberts Ashley Guthrie Raj Prasad Mark S. Gilthorpe Magdy Attia Steven Sourbron |
| author_facet | Mohamed Elsharif Matthew Roche Daniel Wilson Susmita Basak Ian Rowe Dhakshina Vijayanand Richard Feltbower Darren Treanor Lee Roberts Ashley Guthrie Raj Prasad Mark S. Gilthorpe Magdy Attia Steven Sourbron |
| author_sort | Mohamed Elsharif |
| collection | DOAJ |
| description | Abstract Background Post hepatectomy liver failure (PHLF) remains a significant risk in patients undergoing curative liver resection for cancer, however currently available PHLF risk prediction investigations are not sufficiently accurate. The Hepatectomy risk assessment with functional magnetic resonance imaging trial (HEPARIM) aims to establish if quantitative MRI biomarkers of liver function & perfusion can be used to more accurately predict PHLF risk and FLR function, measured against indocyanine green (ICG) liver function test. Methods HEPARIM is an observational cohort study recruiting patients undergoing liver resection of 2 segments or more, prior to surgery patients will have both Dynamic Gadoxetate-enhanced (DGE) liver MRI and ICG testing. Day one post op ICG testing is repeated and R15 compared to the Gadoxetate Clearance (GC) of the future liver remnant (FLR-GC) as measure by preoperative DGE- MRI which is the primary outcome, and preoperative ICG R15 compared to GC of whole liver (WL-GC) as a secondary outcome. Data will be collected from medical records, biochemistry, pathology and radiology reports and used in a multi-variate analysis to the value of functional MRI and derive multivariant prediction models for future validation. Discussion If successful, this test will potentially provide an efficient means to quantitatively assess FLR function and PHLF risk enabling surgeons to push boundaries of liver surgery further while maintaining safe practice and thereby offering chance of cure to patients who would previously been deemed inoperable. MRI has the added benefit of already being part of the routine diagnostic pathway and as such would have limited additional burden on patients time or cost to health care systems. (Hepatectomy Risk Assessment With Functional Magnetic Resonance Imaging - Full Text View - ClinicalTrials.gov , n.d.) Trial registration ClinicalTrials.gov, ClinicalTrials.gov NCT04705194 - Registered 12th January 2021 – Retrospectively registered |
| first_indexed | 2024-12-21T05:00:09Z |
| format | Article |
| id | doaj.art-34971112e17e49b5b8e787c9d241f27e |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-21T05:00:09Z |
| publishDate | 2021-10-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-34971112e17e49b5b8e787c9d241f27e2022-12-21T19:15:16ZengBMCBMC Cancer1471-24072021-10-0121111010.1186/s12885-021-08830-4Hepatectomy risk assessment with functional magnetic resonance imaging (HEPARIM)Mohamed Elsharif0Matthew Roche1Daniel Wilson2Susmita Basak3Ian Rowe4Dhakshina Vijayanand5Richard Feltbower6Darren Treanor7Lee Roberts8Ashley Guthrie9Raj Prasad10Mark S. Gilthorpe11Magdy Attia12Steven Sourbron13Leeds Teaching Hospitals NHS Trust, St James University teaching HospitalLeeds Teaching Hospitals NHS Trust, St James University teaching HospitalLeeds Teaching Hospitals NHS Trust, St James University teaching HospitalBiomedical Imaging Sciences Department, Leeds Institute of Cardiovascular and Metabolic Medicine LIGHT Laboratories, University of LeedsLeeds Teaching Hospitals NHS Trust, St James University teaching HospitalLeeds Teaching Hospitals NHS Trust, St James University teaching HospitalLeeds Institute for Data Analytics, School of Medicine, University of LeedsLeeds Teaching Hospitals NHS Trust, St James University teaching HospitalCardiovascular and Diabetes Research, Leeds Institute of Cardiovascular and Metabolic Medicine LIGHT Laboratories, University of LeedsLeeds Teaching Hospitals NHS Trust, St James University teaching HospitalLeeds Teaching Hospitals NHS Trust, St James University teaching HospitalLeeds Teaching Hospitals NHS Trust, St James University teaching HospitalLeeds Teaching Hospitals NHS Trust, St James University teaching HospitalIICD - SheffieldAbstract Background Post hepatectomy liver failure (PHLF) remains a significant risk in patients undergoing curative liver resection for cancer, however currently available PHLF risk prediction investigations are not sufficiently accurate. The Hepatectomy risk assessment with functional magnetic resonance imaging trial (HEPARIM) aims to establish if quantitative MRI biomarkers of liver function & perfusion can be used to more accurately predict PHLF risk and FLR function, measured against indocyanine green (ICG) liver function test. Methods HEPARIM is an observational cohort study recruiting patients undergoing liver resection of 2 segments or more, prior to surgery patients will have both Dynamic Gadoxetate-enhanced (DGE) liver MRI and ICG testing. Day one post op ICG testing is repeated and R15 compared to the Gadoxetate Clearance (GC) of the future liver remnant (FLR-GC) as measure by preoperative DGE- MRI which is the primary outcome, and preoperative ICG R15 compared to GC of whole liver (WL-GC) as a secondary outcome. Data will be collected from medical records, biochemistry, pathology and radiology reports and used in a multi-variate analysis to the value of functional MRI and derive multivariant prediction models for future validation. Discussion If successful, this test will potentially provide an efficient means to quantitatively assess FLR function and PHLF risk enabling surgeons to push boundaries of liver surgery further while maintaining safe practice and thereby offering chance of cure to patients who would previously been deemed inoperable. MRI has the added benefit of already being part of the routine diagnostic pathway and as such would have limited additional burden on patients time or cost to health care systems. (Hepatectomy Risk Assessment With Functional Magnetic Resonance Imaging - Full Text View - ClinicalTrials.gov , n.d.) Trial registration ClinicalTrials.gov, ClinicalTrials.gov NCT04705194 - Registered 12th January 2021 – Retrospectively registeredhttps://doi.org/10.1186/s12885-021-08830-4Post hepatectomy liver failureRisk assessmentFunctional MRIGadoxetateIndocyanine greenFuture liver remnant |
| spellingShingle | Mohamed Elsharif Matthew Roche Daniel Wilson Susmita Basak Ian Rowe Dhakshina Vijayanand Richard Feltbower Darren Treanor Lee Roberts Ashley Guthrie Raj Prasad Mark S. Gilthorpe Magdy Attia Steven Sourbron Hepatectomy risk assessment with functional magnetic resonance imaging (HEPARIM) BMC Cancer Post hepatectomy liver failure Risk assessment Functional MRI Gadoxetate Indocyanine green Future liver remnant |
| title | Hepatectomy risk assessment with functional magnetic resonance imaging (HEPARIM) |
| title_full | Hepatectomy risk assessment with functional magnetic resonance imaging (HEPARIM) |
| title_fullStr | Hepatectomy risk assessment with functional magnetic resonance imaging (HEPARIM) |
| title_full_unstemmed | Hepatectomy risk assessment with functional magnetic resonance imaging (HEPARIM) |
| title_short | Hepatectomy risk assessment with functional magnetic resonance imaging (HEPARIM) |
| title_sort | hepatectomy risk assessment with functional magnetic resonance imaging heparim |
| topic | Post hepatectomy liver failure Risk assessment Functional MRI Gadoxetate Indocyanine green Future liver remnant |
| url | https://doi.org/10.1186/s12885-021-08830-4 |
| work_keys_str_mv | AT mohamedelsharif hepatectomyriskassessmentwithfunctionalmagneticresonanceimagingheparim AT matthewroche hepatectomyriskassessmentwithfunctionalmagneticresonanceimagingheparim AT danielwilson hepatectomyriskassessmentwithfunctionalmagneticresonanceimagingheparim AT susmitabasak hepatectomyriskassessmentwithfunctionalmagneticresonanceimagingheparim AT ianrowe hepatectomyriskassessmentwithfunctionalmagneticresonanceimagingheparim AT dhakshinavijayanand hepatectomyriskassessmentwithfunctionalmagneticresonanceimagingheparim AT richardfeltbower hepatectomyriskassessmentwithfunctionalmagneticresonanceimagingheparim AT darrentreanor hepatectomyriskassessmentwithfunctionalmagneticresonanceimagingheparim AT leeroberts hepatectomyriskassessmentwithfunctionalmagneticresonanceimagingheparim AT ashleyguthrie hepatectomyriskassessmentwithfunctionalmagneticresonanceimagingheparim AT rajprasad hepatectomyriskassessmentwithfunctionalmagneticresonanceimagingheparim AT marksgilthorpe hepatectomyriskassessmentwithfunctionalmagneticresonanceimagingheparim AT magdyattia hepatectomyriskassessmentwithfunctionalmagneticresonanceimagingheparim AT stevensourbron hepatectomyriskassessmentwithfunctionalmagneticresonanceimagingheparim |